keyword
MENU ▼
Read by QxMD icon Read
search

Long acting atypical injections

keyword
https://www.readbyqxmd.com/read/29722547/adherence-and-economic-impact-of-paliperidone-palmitate-versus-oral-atypical-antipsychotics-in-a-medicare-population
#1
Kruti Joshi, Erik Muser, Yihua Xu, Phil Schwab, Manasi Datar, Brandon Suehs
AIM: To compare adherence, healthcare utilization and costs among real world, Medicare-eligible patients with schizophrenia using long-acting injectable paliperidone palmitate (PP) versus oral atypical antipsychotics. Patients & methods: Historical cohort study used Medicare Advantage claims data. Inverse probability of treatment weighting was applied to adjust for baseline differences. 12-month adherence, healthcare utilization and costs were compared. RESULTS: Patients using PP were more adherent (proportion of days covered ≥0...
May 3, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29694243/budget-impact-analysis-of-long-acting-injectable-aripiprazole-once-monthly-400-mg-in-bipolar-i-disorder-in-the-usa
#2
Margarida Augusto, Mallik Greene, Maëlys Touya, Samantha Min Sweeney, Heidi Waters
AIM: To estimate the budget impact (BI) of introducing aripiprazole once-monthly 400 mg/300 mg (AOM 400) in the maintenance monotherapy treatment of bipolar I disorder versus long-acting injectables, oral antipsychotics and best supportive care. METHODS: A BI model was developed from a US-payer perspective using treatment-related, hospitalization and adverse event management cost estimates for a hypothetical 1,000,000-member health plan over a 5-year period. RESULTS: Market share of AOM 400 was predicted to increase from 0...
April 25, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29623634/a-review-of-clinical-and-economic-evaluations-applied-to-psychotropic-therapies-used-in-the-treatment-of-schizophrenia-in-argentina
#3
REVIEW
Gisela Paula González, Nebel Silvana Moscoso, Fernando Pablo Lago
Schizophrenia is considered a serious mental disorder that affects over 21 million people worldwide, and is associated with disability that frequently affects the patient's educational and working performance. In Argentina, two of the most widely used antipsychotics in the treatment of this disorder are haloperidol and risperidone. Both are provided free to patients without health coverage in public healthcare facilities. In this paper we seek to review the clinical and economic benefits of prescribing psychotropic therapies based on haloperidol (a first-generation antipsychotic that is part of the butyrophenone group of drugs) versus risperidone [an atypical or second-generation antipsychotic (neuroleptic) drug] in adult patients who have been diagnosed with schizophrenia...
October 23, 2017: PharmacoEconomics Open
https://www.readbyqxmd.com/read/29559781/novel-treatment-options-in-depression-and-psychosis
#4
REVIEW
Eva Ceskova, Petr Silhan
In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders. In medicine, there are two main methods of improving the health care provided: seeking new treatment procedures and perfecting (optimizing) the existing ones. Optimization of treatment includes not only practical tools such as therapeutic drug monitoring but also implementation of general trends in the clinical practice. New pharmacological options include new more sophisticated forms of monoaminergic drugs, old drugs rediscovered on the base of a better understanding of pathophysiology of mental illnesses, and drugs aimed at new treatment targets...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29381388/long-acting-injectable-atypical-antipsychotic-use-in-adolescents-an-observational-study
#5
Adriana Fortea, Daniel Ilzarbe, Laura Espinosa, Mireia Solerdelcoll, Clara de Castro, Giovanni Oriolo, Gisela Sugranyes, Inmaculada Baeza
OBJECTIVES: Although second generation long-acting injectable antipsychotics (SG-LAIAs) have been approved and are widely used in adults, there is limited evidence for the use of long-acting formulations in children and adolescents. Thus, we systematically describe the off-label use of SG-LAIAs in clinical practice in adolescent inpatients. METHODS: All individuals admitted to our Children and Adolescent Inpatient Psychiatry Unit receiving treatment with SG-LAIAs between January 2013 and June 2016 were reviewed...
January 30, 2018: Journal of Child and Adolescent Psychopharmacology
https://www.readbyqxmd.com/read/29238631/ethnic-and-age-disparities-in-patients-taking-long-acting-injectable-atypical-antipsychotics
#6
Mateen Soleman, Nikki Lam, Benjamin K Woo
Introduction This study will determine whether different ethnicities and different age groups receive equal amounts of long-acting atypical antipsychotics in comparison to their oral equivalents. Methods Secondary analyses of data from the Los Angeles County Department of Health Services Electronic Health Record (total N=63,134 inpatient visits) were performed. Chi-squared statistics were used to compare ethnicity and age with the use of either risperidone injectable or paliperidone palmitate (r-LAIs) versus risperidone oral...
October 12, 2017: Curēus
https://www.readbyqxmd.com/read/29179595/efficacy-and-safety-of-aripiprazole-lauroxil-once-monthly-versus-aripiprazole-once-monthly-long-acting-injectable-formulations-in-patients-with-acute-symptoms-of-schizophrenia-an-indirect-comparison-of-two-double-blind-placebo-controlled-studies
#7
Chris Cameron, Jacqueline Zummo, Dharmik Desai, Christine Drake, Brian Hutton, Ahmed Kotb, Peter J Weiden
BACKGROUND: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic recently approved for the treatment of schizophrenia. OBJECTIVE: To indirectly compare the safety and efficacy of AL and aripiprazole once-monthly (AOM). METHODS: A systematic search was performed to identify randomized, controlled trials of AOM and AL that met criteria for indirect comparison according to Bayesian network meta-analysis. The analysis indirectly compared AL and AOM treatment groups for efficacy by mean change in Positive and Negative Syndrome Scale (PANSS) total score and ≥30% reduction in PANSS total score, as well as tolerability including adverse events, akathisia, and weight gain...
April 2018: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29179228/can-we-rely-on-agnp-therapeutic-targets-also-for-lai-antipsychotics
#8
Sara Baldelli, Emilio Clementi, Dario Cattaneo
The updated AGNP Consensus Guidelines for Therapeutic Drug Monitoring (TDM) in Neuropsychopharmacology recently published in the journal have reinforced the key role of TDM to individualize psychoparmacological therapies in clinical practice. However, we believe, that these guidelines have missed the important opportunity to face with, and to provide useful information on, the emerging issue of long-acting injectable formulations of atypical antipsychotics. Specific therapeutic ranges also for these formulations should be included in the next AGNP guidelines...
November 27, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/29177572/aripiprazole-lauroxil-a-review-in-schizophrenia
#9
James E Frampton
Aripiprazole lauroxil long-acting injectable (LAI) [Aristada® ] is an intramuscularly administered, extended-release prodrug of aripiprazole, an established atypical antipsychotic agent that, in terms of its relative position within the class, is at the low end of the risk spectrum for metabolic side effects. In the USA, aripiprazole lauroxil LAI is indicated for the treatment of schizophrenia; approved doses of the drug can be injected once-monthly (q4w), every 6 weeks (q6w) or every 2 months (q8w). The efficacy of the 441 and 882 mg q4w dosages in the treatment of acute exacerbations of schizophrenia and as long-term maintenance therapy in stable schizophrenia has been directly demonstrated in a phase III clinical trial and extension, while the efficacy of the 662 mg q4w, 882 mg q6w and 1064 mg q8w dosing regimens has been established on the basis of pharmacokinetic bridging studies...
December 2017: Drugs
https://www.readbyqxmd.com/read/29084192/transient-left-ventricular-dysfunction-due-to-coronary-spasm-after-spinal-anesthesia-with-bupivacaine-a-case-report
#10
Waldemar Elikowski, Małgorzata Małek-Elikowska, Marek Słomczyński, Karolina Horbacka, Jarosław Bartkowski, Bartosz Kalawski
Bupivacaine is a long-acting local anesthetic (LA) used for cutaneous infiltration, peripheral nerve blocks, epidural and spinal anesthesia. However, its application may result in cardiovascular complications such as: hypotension, bradycardia, cardiac arrest and toxic myocardial injury. The authors describe a 53-year-old male with a history of cigarette smoking, admitted for an elective inguinal hernia surgery. Before surgery, the patient received subarachnoid injection of bupivacaine (20 mg). After the operation, he developed transient hypotension...
October 23, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29047368/comparison-and-predictors-of-treatment-adherence-and-remission-among-patients-with-schizophrenia-treated-with-paliperidone-palmitate-or-atypical-oral-antipsychotics-in-community-behavioral-health-organizations
#11
Jeffrey P Anderson, Zeynep Icten, Veronica Alas, Carmela Benson, Kruti Joshi
BACKGROUND: Nonadherence to antipsychotic treatment increases the likelihood of relapse and progressive symptomatology in patients with schizophrenia. Atypical long-acting injectables, including paliperidone palmitate (PP), may increase adherence and improve symptoms. This study compared and assessed predictors of treatment patterns and symptom remission among schizophrenia patients treated with PP versus atypical oral antipsychotic therapy (OAT) in community behavioral health organizations (CBHOs)...
October 18, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28919292/treatment-patterns-health-care-resource-utilization-and-spending-in-medicaid-beneficiaries-initiating-second-generation-long-acting-injectable-agents-versus-oral-atypical-antipsychotics
#12
Dominic Pilon, Neeta Tandon, Marie-Hélène Lafeuille, Rhiannon Kamstra, Bruno Emond, Patrick Lefebvre, Kruti Joshi
PURPOSE: Second-generation long-acting injectable therapies (SGA-LAIs) may reduce health care resource utilization (HRU) and health care costs compared with daily oral atypical antipsychotics (OAAs) in patients with schizophrenia due to reduced dosing frequency, delivery/monitoring by a health care provider, and improved adherence. The aim of the present study was to compare treatment patterns, HRU, and Medicaid spending in patients with schizophrenia initiated on SGA-LAIs (overall and according to agent) versus OAAs...
September 14, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28895766/adherence-persistence-and-inpatient-utilization-among-adult-schizophrenia-patients-using-once-monthly-versus-twice-monthly-long-acting-atypical-antipsychotics
#13
Dominic Pilon, Matthew Alcusky, Yongling Xiao, Philippe Thompson-Leduc, Marie-Hélène Lafeuille, Patrick Lefebvre, Carmela Benson
AIMS: This study compared healthcare resource utilization (HRU), healthcare costs, adherence, and persistence among adult patients with schizophrenia using once-monthly (OM) vs twice-monthly (TM) atypical long-acting injectable (LAI) antipsychotic (AP) therapy. MATERIALS AND METHODS: A longitudinal retrospective cohort study was conducted using Medicaid claims data from six states. Patients initiated on aripiprazole or paliperidone palmitate were assigned to the OM cohort; risperidone-treated patients were assigned to the TM cohort...
February 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/28843143/effects-of-oral-versus-long-acting-antipsychotics-on-social-functioning-a-psychiatrists-survey-in-india
#14
Prasad Rao Gundugurti, Rajesh Nagpal, Ashit Sheth, Prashant Narang, Sonal Gawande, Vikram Singh
BACKGROUND: Schizophrenia is associated with functional challenges for patients; relapses in schizophrenia may lead to increased treatment costs and poor quality of life. OBJECTIVE: This SUSTAIN-I study was conducted to establish psychiatrists' perspective on impact of long-acting injectables (LAIs) antipsychotics on the socio-economic and functional burden of schizophrenia. METHODS: This cross-sectional, survey-based study was conducted in 5 cities in India...
August 9, 2017: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/28754761/directly-observed-therapy-for-clozapine-with-concomitant-methadone-prescription-a-method-for-improving-adherence-and-outcome
#15
Nicholas Tze Ping Pang, Mohd Fadzli Mohamad Isa, Vikram Suarn Singh, Ruziana Masiran
A young male presented with many years of delusions and hallucinations, with concurrent heroin use and subsequent amphetamine uses. There were no depressive or manic symptoms and psychotic symptoms prior to the amphetamine use. After the trials of two atypical antipsychotics and later clozapine due to treatment resistance, adherence and functionality were poor and there was still persistent drug use. As a result, a long acting injectable adjunct was commenced, but only minimal effects were observed. However after initiation of directly observed treatment of clozapine with methadone, there has been functional and clinical response and drug use has ceased...
July 27, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28712616/aripiprazole-lauroxil-compared-with-paliperidone-palmitate-in-patients-with-schizophrenia-an-indirect-treatment-comparison
#16
REVIEW
Chris Cameron, Jacqueline Zummo, Dharmik N Desai, Christine Drake, Brian Hutton, Ahmed Kotb, Peter J Weiden
BACKGROUND: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic recently approved for treatment of schizophrenia on the basis of a large-scale trial of two doses of AL versus placebo. There are no direct-comparison studies with paliperidone palmitate (PP; long-acting antipsychotic used most often in acute settings) for the acute psychotic episode. OBJECTIVES: To indirectly compare efficacy and safety of the pivotal AL study with all PP studies meeting indirect comparison criteria...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28673279/pharmacogenetic-evaluation-to-assess-breakthrough-psychosis-with-aripiprazole-long-acting-injection-a-case-report
#17
Seenae Eum, Mark E Schneiderhan, Jacob T Brown, Adam M Lee, Jeffrey R Bishop
BACKGROUND: Given the complex nature of symptom presentation and medication regimens, psychiatric clinics may benefit from additional tools to personalize treatments. Utilizing pharmacogenetic information may be helpful in assessing unique responses to therapy. We report herein a case of wearing-off phenomena during treatment with aripiprazole long-acting injectable (LAI) and a proof of concept strategy of how pharmacogenetic information may be used to assess possible genetic factors and also hypothesize potential mechanisms for further study...
July 3, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28625204/effect-of-aripiprazole-lauroxil-in-patients-with-acute-schizophrenia-as-assessed-by-the-positive-and-negative-syndrome-scale-supportive-analyses-from-a-phase-3-study
#18
Leslie Citrome, Robert Risinger, Andrew J Cutler, Yangchun Du, Jacqueline Zummo, Henry A Nasrallah, Bernard L Silverman
OBJECTIVE: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic that was evaluated for the treatment of schizophrenia in a randomized, placebo-controlled, Phase 3 study. Here, we present exploratory analyses of supportive efficacy endpoints. METHODS: Patients experiencing an acute exacerbation of schizophrenia received AL 441 mg intramuscularly (IM), AL 882 mg IM, or matching placebo IM monthly. Supportive endpoints included changes from baseline at subsequent time points in Clinical Global Impression-Severity (CGI-S) scale score; Positive and Negative Syndrome Scale (PANSS) Total score; PANSS Positive, Negative, and General Psychopathology subscale scores; PANSS Marder factors (post hoc); and PANSS responder rate...
June 19, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28594483/effect-of-an-institutional-medication-adherence-program-for-long-acting-injectable-risperidone-on-adherence-and-psychiatric-hospitalizations-evidence-from-a-prospective-cohort-study
#19
MULTICENTER STUDY
Jessica J Jalbert, Michel Rossignol, Bernard Astruc, Franck Baylé, Clementine Nordon, Bernard Avouac, Frédéric Rouillon, Lucien Abenhaim, Lamiae Grimaldi-Bensouda
BACKGROUND: Long-acting injectable (LAI) atypical antipsychotics are associated with improved adherence and reduced relapse rates in schizophrenia but reminder-based interventions may further improve outcomes. OBJECTIVES: To assess an institutional medication adherence program's (IMAP) effectiveness on adherence and psychiatric hospitalizations among schizophrenia patients taking risperidone LAI (RLAI). METHODS: Between 2009 and 2010, we recruited patients meeting DSM-IV criteria for schizophrenia treated with RLAI receiving outpatient care from psychiatric centres in France...
May 30, 2017: Journal of Population Therapeutics and Clinical Pharmacology
https://www.readbyqxmd.com/read/28576133/adherence-healthcare-resource-utilization-and-medicaid-spending-associated-with-once-monthly-paliperidone-palmitate-versus-oral-atypical-antipsychotic-treatment-among-adults-recently-diagnosed-with-schizophrenia
#20
Dominic Pilon, Erik Muser, Patrick Lefebvre, Rhiannon Kamstra, Bruno Emond, Kruti Joshi
BACKGROUND: Once-monthly paliperidone palmitate (PP1M) is a long-acting injectable antipsychotic that may increase adherence rates, reduce hospitalizations, and lower medical costs compared to oral atypical antipsychotics (OAAs) among schizophrenia patients. However, the impact of PP1M in recently diagnosed patients remains unknown. The present study compared adherence, healthcare resource utilization and Medicaid spending between schizophrenia patients initiating PP1M versus OAA, among patients recently diagnosed (defined using ages 18-25 years as a proxy) and among the overall population...
June 2, 2017: BMC Psychiatry
keyword
keyword
89519
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"